

RECEIVED
CENTRAL FAX CENTER


DEC 18 2007

In the Claims:

Claims 1 to 13 (cancelled).


Claim 14 (currently amended)

A compound of the formula (I')



wherein

A is



R_{18} , R_{19} and R_{20} are independently selected from the group consisting of hydrogen, -OH, alkyl or alkoxy of 1 to 6 carbon atoms, R_{21} and R_{22} are independently selected from the group consisting of hydrogen and alkyl of 1 to 6 carbon atoms, or R_{21} and R_{22} form together with the nitrogen atom an optionally substituted heterocycle having 4 to 7 members and 1 to 3 heteroatoms including the already present nitrogen atom, the additional heteroatoms being independently selected from the group consisting of O, N or

furthermore R_{21} is selected from the group consisting of alkylsulfonyl, alkylsulfoxide and alkylcarbonyl and then R_{22} is hydrogen,

B is thiophenyl,

X is selected from the group consisting of a bond or $-\text{CO}-\text{NR}_{36}-$,

Y is selected from the group consisting of a bond, $-(\text{CH}_2)_m-$, $-(\text{CH}_2)_r-\text{Q}-(\text{CH}_2)_s-$ and thiazolidine,

Q is selected from the group consisting of piperazine, homopiperazine, 2-methylpiperazine, 2,5-dimethylpiperazine, piperidine, 1,2,3,6-tetrahydropyridine, pyrrolidine, azetidine, thiazolidine and a saturated carbon ring having 3 to 7 members,

Φ is $-(\text{CH}_2)_p-\text{NR}_{37}-(\text{CH}_2)_q-$,

R_{36} and R_{37} are independently selected from the group consisting of hydrogen, alkyl of 1 to 6 carbon atoms and $-\text{CO}-R_{38}$, R_{38} is alkyl or alkoxy of 1 to 6 carbon atoms,

R_{39} is hydrogen,

m, n, p, q, r and s are independently integers from 0 to 6,

and its pharmaceutically acceptable salts.

Claims 15 to 19 (cancelled).

Claim 20 (previously presented) A compound of claim 14 selected from the group consisting of

- 2-amino-N-(4-([amino(2-thienyl)methylidene]amino)phenethyl)-5-methoxybenzamide;
- 5-amino-N-(4-([amino(2-thienyl)methylidene]amino)phenethyl)-2-hydroxybenzamide;
- 4-(4-([amino(2-thienyl)methylidene]amino)phenyl)-N-(4-[(methylsulphonyl)amino]phenyl)butanamide;
- 4-(4-([amino(2-thienyl)methylidene]amino)phenyl)-N-[4-(dimethylamino)phenyl]butanamide;
- 5-(4-([amino(2-thienyl)methylidene]amino)phenyl)-N-[4-(dimethylamino)phenyl]pentanamide;
- (4R)-2-(3-([amino(2-thienyl)methylidene]amino)-phenyl)-N-[4-(dimethylamino)phenyl]-1,3-thiazolidine-4-carboxamide;
- *tert*-butyl 3-([amino(2-thienyl)methylidene]amino)benzyl (3-[4-(dimethylamino)anilino]-3-oxopropyl)carbamate;
- 3-[(3-([amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(4-methyl-1-piperazinyl)phenyl]propanamide;
- 3-[(3-([amino(2-thienyl)methylidene]amino)-benzyl)amino]-N-[4-(4-morpholinyl)phenyl]propanamide;
- N-[4-(2-([5-(dimethylamino)-2-hydroxybenzyl]amino)ethyl)phenyl]-2-thiophenecarboximidamide;
- N-(4-([(4-([amino(2-thienyl)methylidene]amino)phenethyl)-amino]methyl)phenyl)acetamide;

- N¹-(4-(2-([5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]amino)-ethyl)phenyl)-2-thiophenecarboximidamide;

- N¹-(4-(2-([4-(dimethylamino)anilino]carbonyl)amino)-ethyl)phenyl)-2-thiophenecarboximidamide;

- N¹-(4-(2-([5-(dimethylamino)-2-hydroxy-3-methoxybenzyl]-(methyl)amino)ethyl)phenyl)-2-thiophenecarboximidamide;

and the pharmaceutically acceptable salts of the latter.

Claim 21 (withdrawn) A method of inhibiting NO synthase in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

Claim 22 (withdrawn) A method of inhibiting lipidic peroxidation in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

Claim 23 (cancelled).

Claim 24 (withdrawn) A method of treating a neurodegenerative disease in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound of claim 14.

Claim 25 (withdrawn) The method of claim 24 wherein the neurodegenerative disease is selected from the group consisting of Alzheimer's disease,

Huntington's chorea, Parkinson's disease, Creutzfeld Jacob disease and amyotrophic lateral sclerosis.